BioSpace News Archive

SK Biopharmaceuticals announced that the state-run Korea Drug Development Fund has decided to support and finance the company’s development of SKL27969, which is being evaluated as potential treatment for patients with advanced solid tumors, widening SK Biopharmaceuticals’ area into oncology.

Innovent Biologics, Inc. presented the updated results of IBI351 from a phase Ia clinical trial at the 2022 Chinese Society of Clinical Oncology Annual Meeting.

Akeso, Biopharma announced that the Center for Drug Evaluation of the China National Medical Products Administration has granted Breakthrough Therapy Designation for Ivonescimab combined with docetaxel for the treatment of locally advanced or metastatic Non-Small-Cell Lung Carcinoma patients who failed to respond to prior PD-1 inhibitor combined with platinum-based doublet chemotherapy.

InnoCare Pharma, a leading biopharmaceutical company focusing on cancer and autoimmune diseases, announced 2022 third quarter results and latest corporate development.

Shanghai Stock Exchange listed company HitGen Inc. announced that it has entered into a research collaboration agreement with DAEWOONG PHARMACEUTICAL Co., Ltd, a global healthcare group in the Republic of Korea, dedicated to improving the quality of patients’ lives.

BioNTech SE announced its Singapore affiliate BioNTech Pharmaceuticals Asia Pacific Pte. Ltd. had entered into an agreement with Novartis Singapore Pharmaceutical Manufacturing Pte. Ltd. to acquire one of its GMP-certified manufacturing facilities.

Nuance Pharma announces the Center for Drug Evaluation has approved its Investigational New Drug application supporting its pivotal phase III clinical trial of MVA-BN RSV vaccine against respiratory syncytial virus in adults in mainland China.